Daniel Marsh

Daniel Marsh

Senior Markets Analyst

Daniel Marsh is a senior markets analyst at StockTi with over 12 years of experience covering U.S. and global equity markets. He holds a CFA charter and previously worked as an equity research associate at a major Wall Street firm. Daniel specializes in macroeconomic analysis, market trends, and cross-sector investment themes. His work focuses on translating complex market data into actionable insights for individual and institutional investors.

Markets, Economy, Analysis 7,513 articles

Articles by Daniel Marsh

FTSE 250 Suffers Steepest Drop Since March as Rate Fears Bite
Markets

FTSE 250 Suffers Steepest Drop Since March as Rate Fears Bite

The FTSE 250 dropped 1.67% on Tuesday, its steepest loss since March, as rising bond yields and weak mortgage approvals intensified rate-hike expectations.

EWU
Equities Retreat as Oil Prices and Treasury Yields Weigh on Market
Markets

Equities Retreat as Oil Prices and Treasury Yields Weigh on Market

Wall Street's rebound faded as higher oil prices and rising Treasury yields dragged equities lower. The S&P 500 fell 0.64%, while energy shares advanced.

SPY QQQ DIA AAPL MSFT AMD USO GLD XLE XLK XLF XLV
Top 1-Year CD Yields 4.35% APY, Outpacing National Average by 2.64 Points
Economy

Top 1-Year CD Yields 4.35% APY, Outpacing National Average by 2.64 Points

Top one-year CD yields 4.35% APY, beating the 1.71% national average by 2.64 points. A $10,000 deposit earns $435 vs $171, highlighting the value of shopping for rates.

SPY
Sonos Shares Dip 1.5% as Ultra Line Tests Premium Pricing Strategy
Analysis

Sonos Shares Dip 1.5% as Ultra Line Tests Premium Pricing Strategy

Sonos shares slipped 1.5% after unveiling its Ultra lineup, priced 50%+ above standard models, as investors question demand for premium audio gear.

SONO
Apple Rally Trims Nasdaq Loss as Market Breadth Weakens
Markets

Apple Rally Trims Nasdaq Loss as Market Breadth Weakens

Apple's 3% gain helped trim the Nasdaq's midday slide to 0.48%, but breadth remains thin as oil and yields pressure markets. Defensive sectors lead.

AAPL NVDA AMD AXON XLP XLV XLU XLI XLY XLK USO GLD
Novartis Jumps 6% on Remibrutinib Data as Patent Cliff Looms
Analysis

Novartis Jumps 6% on Remibrutinib Data as Patent Cliff Looms

Novartis ADRs jumped 6% after remibrutinib met Phase III endpoints in multiple sclerosis, easing concerns about patent expirations. Stock hit $161.22.

NVS SNY BIIB
KDP's Chobani Exit Yields $925M to Offset Debt
Markets

KDP's Chobani Exit Yields $925M to Offset Debt

Keurig Dr Pepper's sale of its Chobani stake and Pennsylvania plant will generate $925 million, surpassing its 2026 note maturities and supporting debt reduction.

KDP
Alumis Stock Craters 59% on Failed Lupus Trial
Markets

Alumis Stock Craters 59% on Failed Lupus Trial

Alumis shares dropped 59% after its key lupus trial failed to meet primary and secondary endpoints, erasing $1.67 billion in market value.

ALMS
Stocks Trim Losses as Oil Holds Near $88 and Yields Pressurize
Markets

Stocks Trim Losses as Oil Holds Near $88 and Yields Pressurize

U.S. equities trimmed early losses by late morning Tuesday, but the Nasdaq still fell 0.76% as oil near $88 and a 4.77% 10-year yield kept pressure on valuations.

NVDA MU XOM DVN QQQ SPY XLP XLE XLV XLU XLRE XLC XLF XLB XLI XLY XLK
Nokia ADRs Drop 2.9% as AI Order Backlog Faces Profitability Test
Markets

Nokia ADRs Drop 2.9% as AI Order Backlog Faces Profitability Test

Nokia ADRs slid 2.9% to $9.845 as investors weigh the company's €2.8B AI order backlog against negative cash flow and restructuring costs.

ANET CSCO
Fervo Energy Surges 24% on Landmark Google Geothermal Deal
Markets

Fervo Energy Surges 24% on Landmark Google Geothermal Deal

Fervo Energy shares soared 24% after securing a major geothermal power purchase agreement with Google, lifting its market value by $1.1 billion.

GOOGL
bioAffinity Soars 45% on CyPath Surveillance Potential
Markets

bioAffinity Soars 45% on CyPath Surveillance Potential

bioAffinity shares jumped 45% after proposing CyPath Lung for cancer surveillance, with volume 56x shares outstanding.

BIAF